title: Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.
abstract: Ramucirumab is a monoclonal antibody against Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) approved for the treatment of several solid tumours. As shown in recent trials results, new-onset hypertension is one of the most frequent adverse events associated with ramucirumab therapy. Recent studies looked at the quantification of the risk of hypertension in patients receiving other anti-angiogenesis medications. We conducted a meta-analysis of randomized clinical trials with the aim to investigate the incidence and quantify the risk of new-onset hypertension of any grade in patients treated with ramucirumab. Our research suggests that hypertension is frequently associated with ramucirumab therapy, with an OR of 3.60 for any grade of hypertension and an even stronger correlation with grade 3-4 hypertension (OR 4.16). These data suggest that a strict monitoring, as well as early intervention protocols, are recommended in patients receiving the drug.
authors.affiliation: Department of Oncology, Medical Oncology Unit, San Donato Hospital, Via Nenni 20, 52100, Arezzo, Italy. giandomenicoroviello@gmail.com.|Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy. giandomenicoroviello@gmail.com.
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.affiliation: Department of Medical, Surgical and Neurological Sciences, Unit of Raiotherapy, University Hospital Siena, Siena, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Pacifico
authors.affiliation: Radiation Oncology Department, Peter MacCallum Cancer Centre, Moorabbin Campus, East Bentleigh Victoria, 3165, Australia.
authors.forename: Paola
authors.initials: P
authors.lastname: Corona
authors.affiliation: Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.|Unit of Molecular therapy and Pharmacogenomic, ASST Cremona, Viale Concordia 1, 26100, Cremona, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D009369:Neoplasms / Q000188:drug therapy; D012306:Risk; D000096662:Ramucirumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000096662:Ramucirumab
keywords: Gastric cancer; Hypertension; Ramucirumab; Solid tumors